Sponsored Links
| Abbott Receives CE Mark Approval For World's First Drug Eluting Bioresorbable Vascular Scaffold For Treatment Of Coronary Artery Disease |
 |
 |
 |
| Medical News - Clinical Trials and Drug Trials | |||
|
Abbott (NYSE: ABT) announced that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease... Read more: Clinical Trials / Drug Trials News From Medical News Today
|